Professionalism and quality are always at the forefront along the whole value chain: from gene to product. To pro-actively meet the evolving demand of the market to produce new assets Richter-Helm significantly increased its manufacturing capacities for biopharmaceutical products at its production site in Bovenau, Germany.
The biotech and pharma branch is growing steadily. Many companies have full order books for the next few years and expect growth. This is the basis for new investments in assets and infrastructure. These growing structures often expose vulnerabilities and challenges for the business. Therefore, companies need to increase the stability and efficiency of their processes.
Bayer SE subsidiary Asklepios BioPharmaceutical Inc. (AskBio) has started Phase II testing of AB-1002 (NAN-101) in patients with congestive heart failure.
Biovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN.
When businesses receive a proposal from a contract development and manufacturing organisation (CDMO), it’s much like a first date: first impressions matter. The proposal process not only reveals a CDMO’s services but also hints at the potential relationship’s quality. This is gauged mainly through metrics like timing, quality, and price.
Sotio hsd licenced Synaffix’ ADC platform for up to US$740m to develop up to three next generation bioconjugates.
Dyadic International Inc. and bYoRNA SAS partnered to advance innovative bioproduction technologies for scaling up the production of therapeutic mRNA from C1-Cells.
Oxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy.
Bristol-based eXmoor Pharma Ltd has completed a US$35m Series A financing to expand its cell and gene therapy manufacturing capabilities.